Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

New York City boasts more than a dozen world-class research institutions and has been home to Wall Street since Colonial times. It provides an aggregation of scientific, clinical, and entrepreneurial talent, along with investment capital and a range of professional services focused on bioscience. New York City, which is home to 125 life science companies, also offers access to the East Coast pharmaceutical corridor.

Yet, New York is not mentioned in the same breath as San Francisco and Boston, long known for their pioneering biotech efforts and the presence of significant life science communities. How come?

During this week's podcast, Lenzie Harcum from the New York City Economic Development Corporation, and Bill Fair from Alexandria Real Estate Equities, explain why the city is not generally viewed as a major life science cluster. They also discuss initiatives the city is taking to raise awareness about New York's bioscience infrastructure and capabilities. In addition, Harcum and Fair describe the ongoing development of the East River Science Park and the Brooklyn Army Terminal as advanced biotech research centers.

Click the "LISTEN" button above or below for this week's podcast.

Lenzie Harcum is Vice President of Business Development in Biosciences at the New York City Economic Development Corporation.

Bill Fair is Managing Director at Alexandria Real Estate Equities.

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »